Blood Tests to Study Biomarkers in Advanced Thyroid Cancer
Studies blood samples from adults with advanced thyroid cancer to guide treatment choices.
Key facts
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Where
- Bologna, ItalySee the site
- Trial code
- Registry title
- Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas
- Status
- Recruiting
- People taking part
- 10 people, planned
- Started
- 15 Dec 2022
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Treatments tested
- 4 EDTA tubes of peripheral blood for Multigene analysis on ccf-DNA and ccf-RNA
- Record updated
- 7 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced thyroid cancer who are about to start drug treatment that works through the whole body. Blood samples will be studied for tumour markers.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Advanced thyroid cancer (well-differentiated, medullary or anaplastic), confirmed at a central review, who are about to start systemic therapy. The disease must be measurable on scans (CT, or PET-CT with FDG or F-DOPA).
- Earlier treatment
- Cannot have had earlier lines of systemic therapy.
- Biomarker or test result
- Gene testing of the tumour tissue with a multigene NGS panel must already be available.
Main reasons for not taking part
- Already received earlier systemic therapy
- Not able to receive systemic therapy
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Signed written informed consent,
- Adult (≥18 years) male or female patients
- Histologic diagnosis of advanced thyroid carcinoma confirmed at centralized review,
- well-differentiated thyroid carcinomas, medullary thyroid carcinomas, anaplastic thyroid carcinomas, advanced, candidates for initiation of systemic medical therapy,
- Availability of biomolecular profiling performed by multigenic NGS panel on tumor tissue,
- Measurable disease by conventional imaging adopted in clinical practice (total body CT with mdc, CT-PET with FDG or F-DOPA)
Who cannot take part
- Patients already receiving previous lines of systemic therapy,
- Patients not eligible for systemic therapy
Where in Italy
- IRCCS Azienda Ospedaliero universitaria BolognaBologna, ItalyContact: Margherita NanniniTaking people
About the trial
What the trial wants to find out
The study is aimed at all adult patients diagnosed with advanced thyroid carcinomas and well-differentiated thyroid carcinomas (DTC) iodine-refractory, well-differentiated iodine-refractory thyroid (RAI-R DTC) metastatic carcinomas that are candidates for systemic therapy. By simple blood sampling and analysis on peripheral blood of circulating DNA (ccf-DNA), circulating RNA (ccf-RNA), and counting and analysis of circulating tumor cells through the use of liquid biopsy, molecular profiling corresponding to those obtained by genomic sequencing on tumor tissue can be arrived at, depending on optimal therapeutic choices
The group in the trial
- Patients with advanced thyroid carcinomas
Adults patients with advanced thyroid carcinomas will be enrolled.
Treatment: 4 EDTA tubes of peripheral blood for Multigene analysis on ccf-DNA and ccf-RNA
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas
- Plain-language title
- Blood Tests to Study Biomarkers in Advanced Thyroid CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 7 March 2025